Skip to main content

Table 1 Baseline characteristics

From: Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

  Placebo
(n = 228)
Empagliflozin
10 mg
(n = 224)
Empagliflozin
25 mg
(n = 224)
Sitagliptin 100 mg
(n = 223)
Total
(N = 899)
Male 123 (53.9) 142 (63.4) 145 (64.7) 141 (63.2) 551 (61.3)
Age (years) 54.9 ± 10.9 56.2 ± 11.6 53.8 ± 11.6 55.1 ± 9.9 55.0 ± 11.0
Race
 Asian 146 (64.0) 143 (63.8) 144 (64.3) 143 (64.1) 576 (64.1)
 White 76 (33.3) 77 (34.4) 73 (32.6) 76 (34.1) 302 (33.6)
 Black/African-American 6 (2.6) 3 (1.3) 7 (3.1) 3 (1.3) 19 (2.1)
 Other 0 1 (0.4) 0 1 (0.4) 2 (0.2)
Time since diagnosis of T2DM (years)
 ≤1 72 (31.6) 87 (38.8) 91 (40.6) 93 (41.7) 343 (38.2)
 >1–5 104 (45.6) 92 (41.1) 83 (37.1) 86 (38.6) 365 (40.6)
 >5–10 33 (14.5) 29 (12.9) 37 (16.5) 32 (14.3) 131 (14.6)
 >10 19 (8.3) 16 (7.1) 13 (5.8) 12 (5.4) 60 (6.7)
Body weight (kg) 78.2 ± 19.9 78.4 ± 18.7 77.8 ± 18.0 79.3 ± 20.4 78.4 ± 19.2
Body mass index (kg/m2) 28.7 ± 6.2 28.3 ± 5.5 28.2 ± 5.5 28.2 ± 5.2 28.4 ± 5.6
HbA1c (%) 7.91 ± 0.78 7.87 ± 0.88 7.86 ± 0.85 7.85 ± 0.79 7.88 ± 0.82
FPG (mmol/l) 8.6 ± 2.0 8.5 ± 1.8 8.5 ± 1.9 8.2 ± 1.6 8.4 ± 1.8
SBP (mmHg) 130.4 ± 16.3 133.0 ± 16.6 129.9 ± 17.5 132.5 ± 15.8 131.4 ± 16.6
DBP (mmHg) 78.9 ± 9.6 79.2 ± 9.6 78.3 ± 9.4 80.1 ± 10.0 79.1 ± 9.6
eGFR (ml/min/1.73 m2) (MDRD) 86.8 ± 17.9 87.7 ± 19.2 87.6 ± 18.3 87.6 ± 17.3 87.4 ± 18.2
  1. Data are n (%) or mean ± standard deviation in the full analysis set